SunTrust Robinson Humphrey raised its price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Curis (CRIS) Announces FDA Fast Track Designation for Fimepinostat Development in Patients with R/R Diffuse Large B-Cell LymphomaMay 31, 2018 7:03 AM Curis Announces FDA Fast Track Designation for Fimepinostat (CUDC-907) Development in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaMay 31, 2018 7:00 AM